Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.275    -0.245 (-5.42%)
Bid:
4.255
Ask:
4.425
Spread: 0.17 (3.995%)
Market Cap: £205.18m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

Directorate Change

8 Jun 2011 07:00

RNS Number : 0183I
Seeing Machines Limited
08 June 2011
 



8 June 2011

SEEING MACHINES (the "Company")

 

CEO TO DEPART AT END OF CONTRACT

Seeing Machines Limited (AIM:SEE), a leading developer of advanced vision based industrial systems, announces today that CEO and Director Dr Nick Cerneaz will leave the Company in July 2011.

Dr Cerneaz has been with the Company since 2005 and took over as CEO in September 2005 and led the Company at the time of its listing on AIM in December 2005. For the six years that he has been with the company he has commuted to the Canberra head office from his home in Sydney where he lives with his wife and young family. Dr Cerneaz and the Board of Seeing Machines have agreed his tenure as CEO will conclude at the end of this contract. Dr Cerneaz has also agreed to assist the Company in a consulting capacity throughout a handover period as required.

The Board is currently conducting a search for a replacement to lead the Company, as it seeks to move through the next phase of growth and commercialisation. Seeing Machines manufactures a range of world leading products from fatigue management tools through to 3D visualisation and medical technologies, and the Board remains committed to driving a strategy of growth through commercialisation of these technologies and products.

Dr Cerneaz commented: "I have very much enjoyed the efforts and contribution I have made at Seeing Machines and greatly valued the opportunity to work with such a dedicated, professional and energetic team. We have successfully moved the Company through an extensive period of development and laid the foundations for tremendous commercial success ahead, particularly with significant contracts established in our DSS and faceAPI businesses and strong pipelines ahead. I wish to take this opportunity to thank all my colleagues and the stakeholders in the business that have encouraged and supported our efforts and wish the company well in its forward endeavours."

Chairman Bill Mobbs commenting on Dr Cerneaz's departure said: "The Board is extremely grateful to Nick for his leadership of the Company throughout his tenure which was characterised by strong commitment, professionalism, drive and enthusiasm in taking the Company forward. We wish Nick well in his future endeavours and join with everyone at Seeing Machines in thanking Nick wholeheartedly for his efforts on behalf of the Company. "

Enquiries:

Seeing Machines Limited

Bill Mobbs, Chairman

+61 (0) 2 6103 4700

Daniel Stewart & Company plc

Oliver Rigby

+44 (0) 20 7776 6550

Walbrook PR Ltd

 

Paul McManus

 

Paul Cornelius

+44 (0) 20 7933 8780+44 (0) 7980 541 893, paul.mcmanus@walbrookpr.com

+44 (0) 7866 384 707, paul.cornelius@walbrookir.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGMGGVDNRGMZM
Date   Source Headline
27th Mar 20257:11 amRNSBoard Changes
27th Mar 20257:08 amRNSHalf year results and financial report
26th Mar 20258:15 amRNSHolding(s) in Company
24th Mar 20257:00 amRNS-RNew Technology and Safety Leadership Appointments
21st Mar 20257:59 amRNSLondon Town Hall presentation to be live streamed
3rd Mar 202510:18 amRNSNotification of Major Holdings
27th Feb 20257:00 amRNSDirector/PDMR Shareholding
26th Feb 20257:00 amRNSH1 FY2025 Trading Update & Quarterly KPIs
24th Feb 20257:00 amRNSMitsubishi Electric Automotive America Agreement
18th Feb 20257:00 amRNSLondon Presentation
23rd Jan 20257:00 amRNSDirector dealing
21st Jan 20257:00 amRNSDirector/PDMR Shareholding
20th Jan 20257:00 amRNSDirector/PDMR Shareholding
15th Jan 20257:00 amRNSDirector/PDMR Shareholding
15th Jan 20257:00 amRNSDirector/PDMR Shareholding
14th Jan 20257:11 amRNSDirector/PDMR Shareholding
10th Jan 20257:00 amRNSPDMR / Director Dealing
3rd Jan 20257:00 amRNSHolding(s) in Company
31st Dec 202412:27 pmRNSHolding(s) in Company
31st Dec 20248:00 amRNSHolding(s) in Company
31st Dec 20248:00 amRNSPDMR/PCA Dealing
31st Dec 20248:00 amRNSDirector/PDMR Shareholding
31st Dec 20248:00 amRNSDirector/PDMR Shareholding
30th Dec 20247:00 amRNSHolding(s) in Company
30th Dec 20247:00 amRNSDirector/PDMR Shareholding
23rd Dec 20247:00 amRNS£26.2 million strategic investment from Mitsubishi
19th Dec 20247:00 amRNSIssue of Equity and Total Voting Rights
12th Dec 20243:00 pmRNSFY2024 Annual Report
4th Dec 20247:00 amRNS-RLaunch of 2023-24 Guardian Insights Report
27th Nov 20248:49 amRNSResult of AGM
21st Nov 20248:30 amRNSIssue of Shares and Total Voting Rights
11th Nov 20247:00 amRNSQ1 FY2025 Quarterly KPIs
4th Nov 20247:00 amRNSNotice of Annual General Meeting
31st Oct 20247:00 amRNSGlobal regulatory momentum drives revenue growth
17th Oct 20247:00 amRNSNotice of Full Year Results 2024
28th Aug 20247:00 amRNSSeeing Machines FY24 Trading Update
8th Aug 20247:00 amRNSSeeing Machines (SEE) Q4 FY2024 Quarterly KPIs
8th Jul 20247:00 amRNSSeeing Machines acquires Asaphus Vision GmbH
26th Jun 20247:00 amRNSFive year License Renewal with Caterpillar
7th May 20247:00 amRNSQ3 FY2024 Quarterly KPIs
2nd May 202410:30 amRNSDirector/PDMR Shareholding
1st May 20247:00 amRNSAutomotive Program Extension to 2032
26th Apr 202411:00 amRNSDirector/PDMR Shareholding
25th Mar 20248:06 amRNSDirector/PDMR Shareholding
18th Mar 20247:00 amRNSHalf year results and financial report
28th Feb 20247:00 amRNSNotice of Results
8th Feb 20247:00 amRNSH1 FY2024 Trading Update & Quarterly KPIs
10th Jan 20247:00 amRNSNew Orders for Guardian Generation 3
9th Jan 20247:00 amRNSSeeing Machines unveils latest Guardian technology
3rd Jan 20247:00 amRNSSeeing Machines to showcase technology at CES 2024

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.